BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23131904)

  • 1. The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study.
    Han SA; Kim SW; Kang E; Park SK; Ahn SH; Lee MH; Nam SJ; Han W; Bae YT; Kim HA; Cho YU; Chang MC; Paik NS; Hwang KT; Kim SJ; Noh DY; Choi DH; Noh WC; Kim LS; Kim KS; Suh YJ; Lee JE; Jung Y; Moon BI; Yang JH; Son BH; Yom CK; Kim SY; Lee H; Jung SH;
    Fam Cancer; 2013 Mar; 12(1):75-81. PubMed ID: 23131904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Korean Hereditary Breast Cancer (KOHBRA) study: protocols and interim report.
    Han SA; Park SK; Ahn SH; Lee MH; Noh DY; Kim LS; Noh WC; Jung Y; Kim KS; Kim SW;
    Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):434-41. PubMed ID: 21497495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study.
    Kang E; Seong MW; Park SK; Lee JW; Lee J; Kim LS; Lee JE; Kim SY; Jeong J; Han SA; Kim SW;
    Breast Cancer Res Treat; 2015 May; 151(1):157-68. PubMed ID: 25863477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study.
    Son BH; Ahn SH; Kim SW; Kang E; Park SK; Lee MH; Noh WC; Kim LS; Jung Y; Kim KS; Noh DY; Moon BI; Suh YJ; Lee JE; Choi DH; Kim SY; Jung SH; Yom CK; Lee H; Yang JH;
    Breast Cancer Res Treat; 2012 Jun; 133(3):1143-52. PubMed ID: 22382806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
    Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
    Stadler ZK; Salo-Mullen E; Patil SM; Pietanza MC; Vijai J; Saloustros E; Hansen NA; Kauff ND; Kurtz RC; Kelsen DP; Offit K; Robson ME
    Cancer; 2012 Jan; 118(2):493-9. PubMed ID: 21598239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients.
    Kang E; Park SK; Yang JJ; Park B; Lee MH; Lee JW; Suh YJ; Lee JE; Kim HA; Oh SJ; Kim SW;
    Breast Cancer Res Treat; 2012 Aug; 134(3):1189-97. PubMed ID: 22438049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary intake and breast cancer among carriers and noncarriers of BRCA mutations in the Korean Hereditary Breast Cancer Study.
    Ko KP; Kim SW; Ma SH; Park B; Ahn Y; Lee JW; Lee MH; Kang E; Kim LS; Jung Y; Cho YU; Lee B; Lin JH; Park SK
    Am J Clin Nutr; 2013 Dec; 98(6):1493-501. PubMed ID: 24153343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients.
    Kang E; Park SK; Lee JW; Kim Z; Noh WC; Jung Y; Yang JH; Jung SH; Kim SW
    J Hum Genet; 2016 May; 61(5):365-71. PubMed ID: 26763880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
    Sokolenko AP; Sokolova TN; Ni VI; Preobrazhenskaya EV; Iyevleva AG; Aleksakhina SN; Romanko AA; Bessonov AA; Gorodnova TV; Anisimova EI; Savonevich EL; Bizin IV; Stepanov IA; Krivorotko PV; Berlev IV; Belyaev AM; Togo AV; Imyanitov EN
    Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Spectrum of
    Foglietta J; Ludovini V; Bianconi F; Pistola L; Reda MS; Al-Refaie A; Tofanetti FR; Mosconi A; Minenza E; Anastasi P; Molica C; Stracci F; Roila F
    Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32806537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
    Domchek SM; Jhaveri K; Patil S; Stopfer JE; Hudis C; Powers J; Stadler Z; Goldstein L; Kauff N; Khasraw M; Offit K; Nathanson KL; Robson M
    Cancer; 2013 Apr; 119(7):1344-8. PubMed ID: 23165893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically Significant Unclassified Variants in
    Yoon KA; Park B; Lee BI; Yang MJ; Kong SY; Lee ES
    Cancer Res Treat; 2017 Jul; 49(3):627-634. PubMed ID: 27658390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
    Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
    Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
    PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.
    Vencken PM; Kriege M; Hooning M; Menke-Pluymers MB; Heemskerk-Gerritsen BA; van Doorn LC; Collée MM; Jager A; van Montfort C; Burger CW; Seynaeve C
    Cancer; 2013 Mar; 119(5):955-62. PubMed ID: 23165859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
    Hartman AR; Kaldate RR; Sailer LM; Painter L; Grier CE; Endsley RR; Griffin M; Hamilton SA; Frye CA; Silberman MA; Wenstrup RJ; Sandbach JF
    Cancer; 2012 Jun; 118(11):2787-95. PubMed ID: 22614657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
    Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C
    Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.